Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial Evaluating the Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Episodic Migraine

Next Previous
Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial Evaluating the Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Episodic Migraine

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 23 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fremanezumab (Primary)
  • Indications Migraine; Migraine with aura; Migraine without aura
  • Focus Registrational; Therapeutic Use
  • Sponsors Otsuka Pharmaceutical

Most Recent Events

  • 12 Aug 2023 Results of planned exploratory analysis from NCT03303079 and NCT03303092 evaluating quality of life , published in the Headache
  • 29 Jul 2021 Results assessing efficacy and safety of two dosing regimens of fremanezumab in Japanese and Korean patients with episodic migraine published in the Headache
  • 24 Jun 2021 According to a Otsuka Pharmaceutical media release, the company received manufacturing and marketing approval from Ministry of Health, Labour and Welfare (MHLW) in Japan for AJOVY [Fremanezumab] Subcutaneous Injection 225 mg Syringe for the indication of preventive treatment of migraine in adult patients.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top